Stock 4574 TAIKO PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Taiko Pharmaceutical Co.,Ltd.

Equities

4574

JP3442200006

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-01 am EDT 		5-day change 1st Jan Change
351 JPY -0.28% Intraday chart for Taiko Pharmaceutical Co.,Ltd. +5.72% +15.84%
Feb. 09 Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2024 CI
2023 Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 27,942 46,393 69,826 35,911 17,193 15,082
Enterprise Value (EV) 1 21,423 39,223 64,976 34,586 17,497 12,852
P/E ratio 25.3 x 33.1 x 16.7 x -3.74 x -3.51 x -3.97 x
Yield 0.77% 0.76% 1.47% - - -
Capitalization / Revenue 2.95 x 4.45 x 3.11 x 3.18 x 3.41 x 2.46 x
EV / Revenue 2.26 x 3.76 x 2.89 x 3.06 x 3.47 x 2.1 x
EV / EBITDA 9.27 x 15.8 x 9.42 x -8.63 x -7.47 x -42.6 x
EV / FCF 68.7 x 35.6 x 19.7 x -52.7 x 24.3 x 27.3 x
FCF Yield 1.45% 2.81% 5.07% -1.9% 4.12% 3.66%
Price to Book 1.69 x 2.69 x 3.07 x 2.8 x 2.13 x 2.24 x
Nbr of stocks (in thousands) 43,032 42,498 43,317 43,581 43,637 49,776
Reference price 2 649.3 1,092 1,612 824.0 394.0 303.0
Announcement Date 6/28/18 6/27/19 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 9,459 10,418 22,456 11,299 5,040 6,120
EBITDA 1 2,310 2,490 6,901 -4,006 -2,341 -302
EBIT 1 1,857 2,030 6,272 -4,947 -3,078 -1,006
Operating Margin 19.63% 19.49% 27.93% -43.78% -61.07% -16.44%
Earnings before Tax (EBT) 1 1,551 1,985 5,810 -8,888 -4,870 -3,564
Net income 1 1,094 1,415 4,178 -9,594 -4,895 -3,611
Net margin 11.57% 13.58% 18.61% -84.91% -97.12% -59%
EPS 2 25.69 32.96 96.37 -220.5 -112.3 -76.25
Free Cash Flow 1 311.6 1,102 3,294 -656.6 721 470.2
FCF margin 3.29% 10.58% 14.67% -5.81% 14.31% 7.68%
FCF Conversion (EBITDA) 13.49% 44.25% 47.72% - - -
FCF Conversion (Net income) 28.48% 77.86% 78.83% - - -
Dividend per Share 2 5.000 8.333 23.67 - - -
Announcement Date 6/28/18 6/27/19 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3
Net sales 1 6,593 - 5,106 3,249 2,944 6,193 621 1,236 1,857 1,532 1,167 2,488 1,929
EBITDA - - - - - - - - - - - - -
EBIT 1 - - -2,280 702 -3,369 -2,667 -1,672 -745 -2,417 -333 -155 -396 -48
Operating Margin - - -44.65% 21.61% -114.44% -43.06% -269.24% -60.28% -130.16% -21.74% -13.28% -15.92% -2.49%
Earnings before Tax (EBT) 1 - - -2,901 348 - - -1,743 -1,050 -2,793 -387 -242 -492 -45
Net income 1 - - -2,372 425 -7,647 -7,222 -1,748 -1,050 -2,798 -384 -243 -514 -48
Net margin - - -46.46% 13.08% -259.75% -116.62% -281.48% -84.95% -150.67% -25.07% -20.82% -20.66% -2.49%
EPS 2 - - -54.62 9.830 - - -40.13 - -64.17 -8.800 -5.590 -11.36 -0.7300
Dividend per Share - 7.000 - - - - - - - - - - -
Announcement Date 5/14/19 8/12/20 8/6/21 11/9/21 2/18/22 2/18/22 5/13/22 8/12/22 8/12/22 11/11/22 5/12/23 8/10/23 11/10/23
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 304 -
Net Cash position 1 6,519 7,170 4,850 1,325 - 2,230
Leverage (Debt/EBITDA) - - - - -0.1299 x -
Free Cash Flow 1 312 1,102 3,294 -657 721 470
ROE (net income / shareholders' equity) 6.88% 8.35% 13.3% -53.9% -47% -48.9%
ROA (Net income/ Total Assets) 5.91% 6.03% 10.2% -11.4% -10.2% -4.45%
Assets 1 18,503 23,461 41,134 84,234 47,813 81,168
Book Value Per Share 2 384.0 406.0 526.0 294.0 185.0 135.0
Cash Flow per Share 2 153.0 168.0 114.0 133.0 71.30 110.0
Capex 1 129 303 2,860 1,476 64 97
Capex / Sales 1.36% 2.91% 12.74% 13.06% 1.27% 1.58%
Announcement Date 6/28/18 6/27/19 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
TAIKO PHARMACEUTICAL CO.,LTD. Stock Taiko Pharmaceutical Co.,Ltd.
+15.84% 112M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.27% 43.18B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+24.05% 23.23B
SANDOZ GROUP AG Stock Sandoz Group AG
+15.11% 14.6B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+38.36% 11.5B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-7.63% 6.79B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+10.21% 5.31B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-2.27% 4.81B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4574 Stock
  4. Financials Taiko Pharmaceutical Co.,Ltd.